Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine
for treatment of subjects with previously treated or untreated with high risk factor acute
myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients,
and ADI-PEG 20 will be added to this regimen in a phase IA/B study.